Reports of Biochemistry
and Molecular Biology
Mon, Dec 15, 2025
[Archive]
Volume 14, Issue 1 (Vol.14 No.1 Apr 2025)
rbmb.net 2025, 14(1): 10-18 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Fadaee A, Kamal Kheder R, Otaiwe Alrawi R S, Nojoumi M, Esmaeili S, Mansouri A. Update on the Association of CD44 Expression with Esophageal Squamous Cell Carcinoma Invasion. rbmb.net 2025; 14 (1) :10-18
URL: http://rbmb.net/article-1-1612-en.html
URL: http://rbmb.net/article-1-1612-en.html
Afsane Fadaee 
, Ramiar Kamal Kheder , Roaa Saleem Otaiwe Alrawi , Maedeh Nojoumi , Seyed-Alireza Esmaeili , Atena Mansouri *
, Ramiar Kamal Kheder , Roaa Saleem Otaiwe Alrawi , Maedeh Nojoumi , Seyed-Alireza Esmaeili , Atena Mansouri *
Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Abstract: (1012 Views)
Background: Esophageal cancer (EC) is an aggressive gastrointestinal tumor necessitating novel prognostic, diagnostic, and therapeutic strategies. It is essential to identify important markers for diagnosing malignancy and predicting outcomes. Understanding gene functions in signaling pathways and early cancer detection are vital for reducing EC mortality. CD44 upregulation is linked to cancer stem cells (CSC), metastasis, poor prognosis, and treatment response. CD44v6, a variant of CD44, plays a pivotal role in tumor invasion and metastasis by influencing the extracellular matrix, promoting cell motility, and suppressing cancer cell apoptosis.
Methods: This study investigated CD44v6 expression in tumor and tumor-free tissues of the esophagus in 50 esophageal squamous cells carcinomas (ESCC) patients using real-time PCR. The aim was to assess its prognostic value and its correlation with tumor invasion.
Results: Significant overexpression of CD44v6 mRNA was detected in 9 out of 50 tumor specimens (18%, p = 0.0001). CD44v6 expression showed an inverse correlation with tumor cell metastasis to lymph nodes (p = 0.047). Among the 21 patients with lymph node metastasis, 5 (23%) exhibited CD44v6 overexpression. Additionally, CD44v6 expression was linked to the tumor stage (p = 0.008). Specifically, 2 out of 9 patients with stage I tumors (22.2%), 4 out of 9 with stage II tumors (44.4%), and 3 out of 9 with stage III tumors (33.3%) showed CD44v6 overexpression.
Conclusion: Our findings suggest that lower CD44v6 expression at the RNA level correlates with increased tumor invasion and more advanced stages in ESCC.
Methods: This study investigated CD44v6 expression in tumor and tumor-free tissues of the esophagus in 50 esophageal squamous cells carcinomas (ESCC) patients using real-time PCR. The aim was to assess its prognostic value and its correlation with tumor invasion.
Results: Significant overexpression of CD44v6 mRNA was detected in 9 out of 50 tumor specimens (18%, p = 0.0001). CD44v6 expression showed an inverse correlation with tumor cell metastasis to lymph nodes (p = 0.047). Among the 21 patients with lymph node metastasis, 5 (23%) exhibited CD44v6 overexpression. Additionally, CD44v6 expression was linked to the tumor stage (p = 0.008). Specifically, 2 out of 9 patients with stage I tumors (22.2%), 4 out of 9 with stage II tumors (44.4%), and 3 out of 9 with stage III tumors (33.3%) showed CD44v6 overexpression.
Conclusion: Our findings suggest that lower CD44v6 expression at the RNA level correlates with increased tumor invasion and more advanced stages in ESCC.
Type of Article: Original Article |
Subject:
Immunology
Received: 2025/02/28 | Accepted: 2025/06/29 | Published: 2025/12/9
Received: 2025/02/28 | Accepted: 2025/06/29 | Published: 2025/12/9
References
1. Wang D, Plukker JTM, Coppes RP. Cancer stem cells with increased metastatic potential as a therapeutic target for esophageal cancer. Semin Cancer Biol. 2017;44:60-6. [DOI:10.1016/j.semcancer.2017.03.010] [PMID]
2. Arnold M, Laversanne M, Brown LM, Devesa SS, Bray F. Predicting the Future Burden of Esophageal Cancer by Histological Subtype: International Trends in Incidence up to 2030. Am J Gastroenterol. 2017;112(8):1247-55. [DOI:10.1038/ajg.2017.155] [PMID]
3. Tofigh P, Mirghazanfari SM, Hami Z, Nassireslami E, Ebrahimi M. The investigation of Quercus Infectoria Gall Aqueous Extract Effect on the cell proliferation, apoptosis and expression of CCND1, TP53, BCL2 and BAX genes in cell line of lung, gastric and esophageal cancers. Rep Biochem Mol Biol.. 2024;12(4):596-608. [DOI:10.61186/rbmb.12.4.596] [PMID] []
4. Zhao JS, Li WJ, Ge D, Zhang PJ, Li JJ, Lu CL, et al. Tumor initiating cells in esophageal squamous cell carcinomas express high levels of CD44. PLoS One. 2011;6(6):e21419. [DOI:10.1371/journal.pone.0021419] [PMID] []
5. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. Erratum in: CA Cancer J Clin. 2011; 61(2):133-4. [DOI:10.3322/caac.20105]
6. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349(23):2241-52. [DOI:10.1056/NEJMra035010] [PMID]
7. Hosseini S, Chamani J, Rahimi H, Azmoodeh N, Ghasemi F, Abadi PH. An in vitro study on curcumin delivery by nano-micelles for esophageal squamous cell carcinoma (KYSE-30). Rep Biochem Mol Biol. 2018;6(2):137-143.
8. Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. The oncologist. 2005;10(8):590-601. [DOI:10.1634/theoncologist.10-8-590] [PMID]
9. Spechler SJ. Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA. 2013;310(6):627-36. [DOI:10.1001/jama.2013.226450] [PMID]
10. Roshandel G, Nourouzi A, Pourshams A, Semnani S, Merat S, Khoshnia M. Endoscopic screening for esophageal squamous cell carcinoma. Arch Iran Med. 2013;16(6):351-7.
11. Yu SS, Cirillo N. The molecular markers of cancer stem cells in head and neck tumors. J Cell Physiol. 2020;235(1):65-73. [DOI:10.1002/jcp.28963] [PMID]
12. Nozoe T, Kohnoe S, Ezaki T, Kabashima A, Maehara Y. Significance of immunohistochemical over-expression of CD44v6 as an indicator of malignant potential in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2004;130(6):334-8. [DOI:10.1007/s00432-004-0542-2] [PMID] []
13. Wang C, Xie J, Guo J, Manning HC, Gore JC, Guo N. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Oncol Rep. 2012;28(4):1301-8. [DOI:10.3892/or.2012.1951] [PMID] []
14. Lu L, Wu M, Sun L, Li W, Fu W, Zhang X, Liu T. Clinicopathological and prognostic significance of cancer stem cell markers CD44 and CD133 in patients with gastric cancer: A comprehensive meta-analysis with 4729 patients involved. Medicine. 2016;95(42):e5163. [DOI:10.1097/MD.0000000000005163] [PMID] []
15. Lin YH, Yang-Yen HF. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem. 2001;276(49):46024-30. [DOI:10.1074/jbc.M105132200] [PMID]
16. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997;71:241-319. [DOI:10.1016/S0065-230X(08)60101-3] [PMID]
17. Gomez KE, Wu F, Keysar SB, Morton JJ, Miller B, Chimed TS, et al. Cancer Cell CD44 Mediates Macrophage/Monocyte-Driven Regulation of Head and Neck Cancer Stem Cells. Cancer Res. 2020;80(19):4185-98. [DOI:10.1158/0008-5472.CAN-20-1079] [PMID] []
18. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol Pathol. 1999;52(4):189-96. [DOI:10.1136/mp.52.4.189] [PMID] []
19. Ouhtit A, Madani S, Gupta I, Shanmuganathan S, Abdraboh ME, Al-Riyami H, et al. TGF-beta2: A Novel Target of CD44-Promoted Breast Cancer Invasion. J Cancer.4(7):566-72. [DOI:10.7150/jca.6638] [PMID] []
20. Bellizzi A, Sebastian S, Ceglia P, Centonze M, Divella R, Manzillo EF, et al. Co-expression of CD133(+)/CD44(+) in human colon cancer and liver metastasis. J Cell Physiol.228(2):408-15. [DOI:10.1002/jcp.24145] [PMID]
21. Jin YJ, Termsarasab U, Ko SH, Shim JS, Chong S, Chung SJ, et al. Hyaluronic acid derivative-based self-assembled nanoparticles for the treatment of melanoma. Pharm Res.29(12):3443-54. [DOI:10.1007/s11095-012-0839-9] [PMID]
22. Khurana SS, Riehl TE, Moore BD, Fassan M, Rugge M, Romero-Gallo J, et al. The hyaluronic acid receptor CD44 coordinates normal and metaplastic gastric epithelial progenitor cell proliferation. J Biol Chem.288(22):16085-97. [DOI:10.1074/jbc.M112.445551] [PMID] []
23. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 2002;16(23):3074-86. [DOI:10.1101/gad.242602] [PMID] []
24. Bourguignon LY, Zhu H, Shao L, Zhu D, Chen YW. Rho-kinase (ROK) promotes CD44v(3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell Motil Cytoskeleton. 1999;43(4):269-87.
https://doi.org/10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5 [DOI:10.1002/(SICI)1097-0169(1999)43:43.0.CO;2-5]
25. Lesley J, English NM, Gál I, Mikecz K, Day AJ, Hyman R. Hyaluronan binding properties of a CD44 chimera containing the link module of TSG-6. J Biol Chem. 2002;277(29):26600-8. [DOI:10.1074/jbc.M201068200] [PMID]
26. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem cells. 2009;27(5):1006-20. [DOI:10.1002/stem.30] [PMID] []
27. Mahmoudian RA, Golyan FF, Forghanifard MM, Gholamin M, Mansouri A, Tanzadehpanah H, et al. Exploring the role of LINC-ROR in epithelial-mesenchymal transition and its correlation with CD44 and TWIST1 in gastric cancer progression. Hum Gene. 2025;44(1):201394. [DOI:10.1016/j.humgen.2025.201394]
28. Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004;64(15):5245-50. [DOI:10.1158/0008-5472.CAN-04-0496] [PMID]
29. Xu H, Niu M, Yuan X, Wu K, Liu A. CD44 as a tumor biomarker and therapeutic target. Exp Hematol Oncol. 2020;9(1):36. [DOI:10.1186/s40164-020-00192-0] [PMID] []
30. Jung T, Gross W, Zoeller M. CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance. J Biol Chem. 2011;286(18):15862-74. [DOI:10.1074/jbc.M110.208421] [PMID] []
31. Gun BD, Bahadir B, Bektas S, Barut F, Yurdakan G, Kandemir NO, Ozdamar SO. Clinicopathological significance of fascin and CD44v6 expression in endometrioid carcinoma. Diagn Pathol. 2012;7:80. [DOI:10.1186/1746-1596-7-80] [PMID] []
32. Friedrichs K, Kügler G, Franke F, Terpe HJ, Arlt J, Regidor PA, Günthert U. CD44 isoforms in prognosis of breast cancer. Lancet. 1995;345(8959):1237. [DOI:10.1016/S0140-6736(95)92018-8] [PMID]
33. Ghaffari S, Smadja-Joffe F, Oostendorp R, Lévesque JP, Dougherty G, Eaves A, Eaves C. CD44 isoforms in normal and leukemic hematopoiesis. Exp Hematol. 1999;27(6):978-93. [DOI:10.1016/S0301-472X(99)00023-5] [PMID]
34. Du L, Rao G, Wang H, Li B, Tian W, Cui J, et al. CD44-positive cancer stem cells expressing cellular prion protein contribute to metastatic capacity in colorectal cancer. Cancer Res.73(8):2682-94. [DOI:10.1158/0008-5472.CAN-12-3759] [PMID]
35. Carinci F, Stabellini G, Calvitti M, Pelucchi S, Targa L, Farina A, et al. CD44 as prognostic factor in oral and oropharyngeal squamous cell carcinoma. J Craniofac Surg. 2002;13(1):85-9. [DOI:10.1097/00001665-200201000-00020] [PMID]
36. Lagorce-Pages C, Paraf F, Dubois S, Belghiti J, Flejou JF. Expression of CD44 in premalignant and malignant Barrett's oesophagus. Histopathology. 1998;32(1):7-14. [DOI:10.1046/j.1365-2559.1998.00316.x] [PMID]
37. Zaiden M, Feinshtein V, David A. Inhibition of CD44v3 and CD44v6 function blocks tumor invasion and metastatic colonization. J Control Release. 2017;257:10-20. [DOI:10.1016/j.jconrel.2017.01.021] [PMID]
38. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer.46(7):1271-7. [DOI:10.1016/j.ejca.2010.02.024] [PMID]
39. Suzuki H, Yamashiro K. Reduced expression of CD44 v3 and v6 is related to invasion in lung adenocarcinoma. Lung Cancer. 2002;38(2):137-41. [DOI:10.1016/S0169-5002(02)00176-9] [PMID]
40. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci. 2002;39(6):527-79. [DOI:10.1080/10408360290795574] [PMID]
41. Heider KH, Kuthan H, Stehle G, Munzert G. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother. 2004;53:567-79. [DOI:10.1007/s00262-003-0494-4] [PMID] []
42. Li XD, Ji M, Wu J, Jiang JT, Wu CP. Clinical significance of CD44 variants expression in colorectal cancer. Tumori. 2013;99(1):88-92. [DOI:10.1177/030089161309900115] [PMID]
43. Da Cunha CB, Oliveira C, Wen X, Gomes B, Sousa S, Suriano G, et al. De novo expression of CD44 variants in sporadic and hereditary gastric cancer. Lab Invest. 2010;90(11):1604-14. [DOI:10.1038/labinvest.2010.155] [PMID]
44. Mansouri A, Foroughmand AM, Abbaszadegan MR, Memar B, Mahmoudian RA, Gholamin M. Expression analysis of CD44 isoforms S and V3, in patients with esophageal squamous cell carcinoma. Iran J Basic Med Sci. 2015;18(4):380-4.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
